Xencor (XNCR) Income from Continuing Operations (2013 - 2026)
Xencor (XNCR) reported Income from Continuing Operations of 128916000.0 for Q1 2026, down 164.9% year-over-year from 198622717.03 in Q1 2025, and down 1832.77% quarter-over-quarter from 6670000.0 in Q4 2025.
Xencor (XNCR) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Income from Continuing Operations data on file, last reported at 128916000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 128916000.0, down 164.9% year-over-year; the trailing twelve-month figure through Mar 2026 was 172388000.0 (up 18.33% YoY), and the FY2025 annual result was 92137000.0, up 61.05% from the prior year.
- Income from Continuing Operations declined to 128916000.0 in Q1 2026 per XNCR's latest filing, from 6670000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 26466000.0 in Q1 2022 and troughed at 128916000.0 in Q1 2026.
- A 5-year average of 37550764.71 and a median of 30775000.0 in 2025 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 268.87% in 2022 and fell as far as 408.13% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 12042000.0 in 2022, then plunged by 118.49% to 26310000.0 in 2023, then plunged by 75.6% to 46200000.0 in 2024, then jumped by 85.56% to 6670000.0 in 2025, then plunged by 1832.77% to 128916000.0 in 2026.
- Business Quant data shows XNCR's Income from Continuing Operations at 128916000.0 in Q1 2026, 6670000.0 in Q4 2025, and 6027000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -128.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.92 Mn |
| Dec 31, 2025 | -6.67 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -30.78 Mn |
| Mar 31, 2025 | -48.67 Mn |
| Dec 31, 2024 | -46.20 Mn |
| Sep 30, 2024 | -47.44 Mn |
| Jun 30, 2024 | -68.78 Mn |
| Mar 31, 2024 | -74.12 Mn |
| Dec 31, 2023 | -26.31 Mn |
| Sep 30, 2023 | -24.27 Mn |
| Jun 30, 2023 | -26.00 Mn |
| Mar 31, 2023 | -57.85 Mn |
| Dec 31, 2022 | -12.04 Mn |
| Sep 30, 2022 | -32.76 Mn |
| Jun 30, 2022 | -28.00 Mn |
| Mar 31, 2022 | 26.47 Mn |
| Dec 31, 2021 | 73.06 Mn |
| Sep 30, 2021 | -40.19 Mn |
| Jun 30, 2021 | 9.09 Mn |